Last reviewed · How we verify
Cefuroxime Axetil Dispersible Tablets
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Acute bacterial exacerbation of chronic bronchitis, Acute bacterial sinusitis, Pharyngitis.
At a glance
| Generic name | Cefuroxime Axetil Dispersible Tablets |
|---|---|
| Sponsor | Jiangsu Famous Medical Technology Co., Ltd. |
| Drug class | Cephalosporin antibiotic |
| Target | Penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Cefuroxime axetil is a second-generation cephalosporin antibiotic that exerts its antibacterial effects by inhibiting the synthesis of the bacterial cell wall through the binding of penicillin-binding proteins.
Approved indications
- Acute bacterial exacerbation of chronic bronchitis
- Acute bacterial sinusitis
- Pharyngitis
- Skin and skin structure infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Dizziness
- Fatigue
- Insomnia
- Rash
- Pruritus
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: